| symbol |
NITE |
|---|
| 会社名 | Nightstar Therapeutics PLC （ナイトスタ―・セラピュ―ティクス） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Biotechnology: Biological Products (No Diagnostic Substances)
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Nightstar Therapeutics PLC formerly Nightstar Therapeutics Limited is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate NSR-REP1 for the treatment of choroideremia or CHM is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate NSR-RPGR for the treatment of X-linked retinitis pigmentosa or XLRP. The Company’s third product candidate NSR-BEST1 is in preclinical development for the treatment of Best vitelliform macular dystrophy or Best disease. ナイトスタ―・セラピュ―ティクスはイギリスの医薬品企業。臨床段階で、遺伝性網膜疾患に対する遺伝子治療の開発・商業化に従事する。承認された治療法がなくし、一度の遺伝子治療で網膜疾患の進行を改変または停止するように設計された独自のパイプラインを開発する。同社の医薬品候補「NSR-REP1」はチロイド血症やCHMの治療を行う。本社所在地はロンドン。 Nightstar Therapeutics plc is a clinical-stage gene therapy holding company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
|
|---|
| 本社所在地 | 215 Euston Road London NW1 2BE GBR |
|---|
| 代表者氏名 | ― |
|---|
| 代表者役職名 | ― |
|---|
| 電話番号 | +44 20-7611-2077 |
|---|
| 設立年月日 | 42917 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2017年 |
|---|
| 従業員数 | 27人 |
|---|
| url | www.nightstartx.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/nite |
|---|
| adr_tso | 6398757 |
|---|
| EBITDA | EBITDA（百万ドル） -37.05200 |
|---|
| 終値（lastsale） | 16.96 |
|---|
| 時価総額（marketcap） | 108522918.72 |
|---|
| 時価総額 | 時価総額（百万ドル） 461.03510 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 349.67410 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -44.44700 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Nightstar Therapeutics PLC revenues was not reported. Net loss increased from $7.7M to $22.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.27 to -$0.80. |
|---|
NITE - ナイトスタ―・セラピュ―ティクス （Nightstar Therapeutics plc） ナイトスタ―・セラピュ―ティクス